FDA Plans to Combat Teen Vaping

FDA focuses on Juuling

On November 15, the U.S. Food and Drug Administration (FDA) released a statement in response to the spike in teen e-cigarette use. In an effort to protect minors from e-cigarettes like JUUL, the agency has plans to ban flavored options and develop therapies for youth cessation. These actions are part of the Youth Tobacco Prevention Plan, first released in April 2018, as an expansion of the FDA's Comprehensive Plan for Nicotine and Tobacco Regulation.

The FDA's New Steps

With 1.5 million more students smoking e-cigarettes in 2018 than the previous year, FDA Commissioner Scott Gottlieb considers youth e-cigarette use an epidemic. In his statement, Gottlieb noted that the incline of combustible cigarette use in teens is a result of the easy accessibility and youth-targeted marketing tactics of their electronic counterparts. The unsafe ingredients in e-cigarettes have the potential to stir up many health risks, especially for teens, and many are taking notice.

Since teens are often attracted to the flavored aspect of e-cigarettes, the sale of flavored pods has been closely under review and ultimately deemed dangerous enough to remove from the market. In the November press release, flavored cigars were also added to the list of products to be banned to keep youth safe and tobacco-free.

Although mint- and menthol-flavored e-cigarettes are still on the market, as well as in combustible cigarette form, Gottlieb noted that many of the current regulations and requests may change if there is no progress in cutting back on teen usage. To aid in the effort, plans to develop and support therapy for teen tobacco cessation are also underway.

Preventing JUUL Addiction

Since the initial launch of the Youth Tobacco Prevention Plan, the FDA prioritized enforcing age restrictions on the products, removing them from online retailers such as Ebay. They also released a series of videos as a prevention campaign, titled "The Real Cost," which was implemented to educate youth on the risks of smoking cigarettes and e-cigarettes.

In September, a warning was issued to manufacturers such as JUUL that required them to undergo a premarket review of their products. Manufacturers were given 60 days to respond with a plan of action to prevent e-cigarettes from getting in the hands of minors, most of which were expected to include secure age-verified online sales, elimination of flavored pods until reviewed by the FDA, and new marketing campaigns.

Nicotine plays a crucial role in conventional cigarette and e-cigarette addiction. Because of this, along with other dangerous ingredients, nicotine poses major threats to young people. In 2017, the FDA even started working on plans to reduce the nicotine levels in conventional cigarettes, which was part of their initial tobacco regulation framework.

The Future of the Teen E-Cigarette Crisis

This may not be the end of updates to come for the e-cigarette and tobacco market, as the FDA continues to monitor usage trends and determine next steps. There will be an FDA hearing on December 5 to discuss a plan of action moving forward and further strategies to develop drug therapies to those with a vaping addiction quit.

Regardless of potential rules from the FDA, JUUL and other e-cigarette makers are facing more and more vaping lawsuits. Given the many dangerous health effects of e-cigarettes that could lead to damages awarded by juries, perhaps those e-cigarette lawsuits will succeed where government regulations have failed.

Authored by Katy Moncivais, Ph.D.Medical Editor
Photo of Katy Moncivais, Ph.D.
Katy Moncivais holds a Ph.D. in Biomedical Engineering from The University of Texas at Austin. She’s an experienced Regenerative Medicine Consultant with a demonstrated history of working in the hospital & healthcare industry. Skilled in adult stem cells, medical devices, biomechanics, bacterial and mammalian cell culture, and regenerative medicine, she provides guidance on an array of topics affecting consumers. In her role at ConsumerSafety.org, Dr. Moncivais works alongside the writing and research staff to help deliver fact-based news stories to consumers. Her unique professional history alongside her rigorous educational background allows her to contribute to a variety of consumer-focused topics with a fresh perspective. In addition, Dr. Moncivais reviews portions of medically driven content to ensure scientific accuracy.
Editorial Standards Full Bio